Toremifene
Links shared publicly online about this topic
Ipsen, Gtx terminate collaboration for development and commercialization of toremifene
news-medical.net — “GTx, Inc. today announced that the company and Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene.” View full resource at news-medical.net
Most Recently Shared on March 2, 2011 at 4:52 pm By:
Prostate Cancer: Ipsen, Gtx terminate collaboration for development and commercialization of toremifene: GTx, In... http://bit.ly/fqcs4E
Phase 3 trial of toremifene for prostate cancer - ONA
oncologynurseadvisor.com — “GTx Incorporated announced top line results of its Phase 3 trial evaluating toremifene 20mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a premalignant lesion of the prostate.” View full resource at oncologynurseadvisor.com
Most Recently Shared on May 26, 2010 at 7:35 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 3 trial of toremifene for prostate cancer http://goo.gl/fb/CHJJG
Ipsen, GTx expand partnership for toremifene 80 mg
news-medical.net — “Ipsen today announced the expansion of their partnership for the development and commercialization of toremifene 80 mg for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy (ADT) and toremifene 20 mg for the prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN).” View full resource at news-medical.net
Most Recently Shared on March 23, 2010 at 7:18 am By:
Ipsen, GTx expand partnership for toremifene 80 mg: Ipsen today announced the expansion of their partnership for t... http://bit.ly/9hLVKh
Phase 3 trial of toremifene for prostate cancer - MPR
empr.com — “GTx Incorporated announced top line results of its Phase 3 trial evaluating toremifene 20mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a premalignant lesion of the prostate.” View full resource at empr.com
Most Recently Shared on May 26, 2010 at 7:45 pm By:
MPR News: Phase 3 trial of toremifene for prostate cancer: GTx Incorporated announced top line results of its Phas... http://bit.ly/cDZLou
FDA issues a Complete Response Letter for GTx' toremifene NDA
news-medical.net — “GTx, Inc. today announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT).” View full resource at news-medical.net
Most Recently Shared on November 2, 2009 at 6:26 pm By:
Prostate Cancer: FDA issues a Complete Response Letter for GTx' toremifene NDA: GTx, Inc. today.. http://bit.ly/41AWz5
GTx reports positive results from toremifene Phase III clinical trial
news-medical.net — “GTx, Inc. announced today that in the Phase III clinical trial evaluating toremifene 80 mg for the reduction of fractures and treatment of other estrogen deficiency side effects in men with prostate cancer on androgen deprivation therapy (ADT), toremifene treatment demonstrated an improved benefit/risk ratio in men less than 80 years of age. The data were presented yesterday at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.” View full resource at news-medical.net
Most Recently Shared on June 8, 2010 at 6:29 pm By:
Prostate Cancer: GTx reports positive results from toremifene Phase III clinical trial: GTx, Inc. announced today ... http://bit.ly/aY94OK
Full report on the toremifene Phase III fracture prevention trial « THE "NEW" PROSTATE CANCER INFOLINK
prostatecancerinfolink.net — “Full report on the toremifene Phase III fracture prevention trial « THE "NEW" PROSTATE CANCER INFOLINK” View full resource at prostatecancerinfolink.net
Most Recently Shared on November 11, 2010 at 2:09 pm By:
john clay mchugh Surgeon, Urologist, Physician, and Doctor
Full report on the toremifene Phase III fracture prevention trial: Toremifene is a selective estrogen receptor m... http://bit.ly/cnAkiA
Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy
news-medical.net — “GTx, Inc. today announced that additional study results from the Phase III clinical trial evaluating toremifene 80 mg for the prevention of fractures in men with prostate cancer on androgen deprivation therapy will be presented at the 2010 Annual Meeting of the American Urological Association being held in San Francisco May 29-June 3.” View full resource at news-medical.net
Most Recently Shared on May 27, 2010 at 12:48 pm By:
Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy: GTx... http://bit.ly/9PJuyz
GTx to continue its toremifene Phase III high grade PIN clinical trial for prevention of prostate cancer
news-medical.net — “GTx, Inc. (Nasdaq: GTXI), today announced that following a planned safety review, an independent Data Safety Monitoring Board (DSMB) has recommended that the company continue as planned the pivotal Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a precancerous lesion of the prostate.” View full resource at news-medical.net
Most Recently Shared on September 14, 2009 at 1:05 pm By:
Prostate Cancer: GTx to continue its toremifene Phase III high grade PIN clinical trial for prev.. http://bit.ly/ydD7H
GTx Announces Top Line Results Of Phase III Trial Evaluating Toremifene 20 Mg For The Prevention Of Prostate Cancer In Men With High Grade PIN
medicalnewstoday.com — “GTx, Inc. (Nasdaq: GTXI) announced top line results of the Phase III clinical trial evaluating toremifene 20 mg, a selective estrogen receptor modulator, for the prevention of prostate cancer in m” View full resource at medicalnewstoday.com
Most Recently Shared on May 27, 2010 at 7:21 am By:
Urology & Nephrology OW Health
GTx Announces Top Line Results Of Phase III Trial Evaluating Toremifene 20 Mg For The Prevention Of Prostate Cance... http://mnt.to/f/3D8n
GTx reports top line results from toremifene Phase III clinical trial for prostate cancer in men with high grade PIN
news-medical.net — “GTx, Inc. today announced top line results of the Phase III clinical trial evaluating toremifene 20 mg, a selective estrogen receptor modulator, for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia, or PIN, a premalignant lesion of the prostate.” View full resource at news-medical.net
Most Recently Shared on May 26, 2010 at 4:37 am By:
Prostate Cancer: GTx reports top line results from toremifene Phase III clinical trial for prostate cancer in men ... http://bit.ly/bFo8Yf
GTx Announces Upcoming AUA Presentation of Additional Study Results from the Phase III Clinical Trial Evaluating Toremifene 80 mg for the Reduction of Fractures in Men with Prostate Cancer on ADT - News Press Release | PharmiWeb.com
pharmiweb.com — “GTx Announces Upcoming AUA Presentation of Additional Study Results from the Phase III Clinical Trial Evaluating Toremifene 80 mg for the Reduction of Fractures in Men with Prostate Cancer on ADT - News Press Release | PharmiWeb.com” View full resource at pharmiweb.com
Most Recently Shared on May 27, 2010 at 8:58 pm By:
Endocrinology Wisdom OW Health
Press Release: GTx Inc. Posted on:27 May 10 GTx, Inc. (NASDAQ: GTXI) today announced that additional study results... http://bit.ly/9RIQH5
Family Medicine Article | Breast Neoplasms
mdlinx.com — “The Effect of Toremifene on Lipid Metabolism Compared with That of Tamoxifen in vitro” View full resource at mdlinx.com
Most Recently Shared on May 7, 2011 at 2:51 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
The Effect of Toremifene on Lipid Metabolism Compared with That of Tamoxifen in vitro: Gynecologic ... http://bit.ly/iPveUg #FamPractice
Prostate Cancer: Reducing Fracture Risk in Men on Androgen Deprivation Therapy - QualityPoint Technologies
qualitypointtech.net — “Should toremifene be prescribed routinely to treat osteoporosis in the setting of ADT for prostate cancer? Nature Reviews Urology” View full resource at qualitypointtech.net
Most Recently Shared on March 18, 2011 at 11:35 am By:
Prostate Cancer: Reducing Fracture Risk in Men on Androgen Deprivation Therapy: Should toremifene be prescribed ro... http://bit.ly/fyPKya
Family Medicine Article | Breast Neoplasms
mdlinx.com — “Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: The results of a 2-year multicenter open randomized study” View full resource at mdlinx.com
Most Recently Shared on June 9, 2011 at 3:53 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females... http://bit.ly/mFpyAo #FamPractice
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
News-Medical.Net
Stay up to date with the latest prostate cancer news and research via News-Medical.Net
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
-
News-Medical.Net
Medical News from Around the World
Advertisement
